Experimental HCV Drugs
Experimental HCV Drugs
DDW 2013: Advanced Fibrosis Does Not Affect Response to Faldaprevir All-oral Regimen
- Details
- Category: HCV Treatment
- Published on Wednesday, 22 May 2013 00:00
- Written by Liz Highleyman
An interferon-free combination of faldaprevir, BI 207127, and ribavirin produced high and similar sustained response rates for treatment-naive genotype 1b hepatitis C patients with either absent-to-moderate liver fibrosis or advanced fibrosis/cirrhosis, according to a presentation at the Digestive Disease Week conference (DDW 2013) this week in Orlando.
DDW 2013: Simeprevir Boosts Response to Interferon-based Therapy for Prior Relapsers
- Details
- Category: HCV Treatment
- Published on Wednesday, 22 May 2013 00:00
- Written by Liz Highleyman
Adding the HCV protease inhibitor simeprevir (formerly TMC435) to pegylated interferon and ribavirin cured 79% of prior relapsers, and most were eligible to complete treatment after 3 months, according to findings from the PROMISE study presented at the Digestive Disease Week meeting (DDW 2013) this week in Orlando.
HCV Protease Inhibitor Simeprevir Granted FDA Priority Review Status
- Details
- Category: HCV Treatment
- Published on Wednesday, 15 May 2013 00:00
- Written by Janssen
On May 13, Janssen announced that its application for approval of the next-generation hepatitis C virus NS3/4A protease inhibitor simeprevir (formerly TMC435) has received priority review status from the U.S. Food and Drug Administration (FDA), giving it an estimated timeline of 6 months.
Coverage of Digestive Disease Week 2013
- Details
- Category: HBV Treatment
- Published on Wednesday, 22 May 2013 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the 2013 Digestive Disease Week annual meeting (DDW 2013) in Orlando, Florida, May 18-21, 2013.
Conference highlights include direct-acting hepatitis C drugs, new strategies for using approved HCV protease inhibitors and interferon/ribavirin, and interferon-free regimens.
HIVandHepatitis.com DDW 2013 conference section
5/22/13
EASL 2013: Direct-acting Antivirals Boost Response to Pegylated Interferon/Ribavirin
- Details
- Category: HCV Treatment
- Published on Wednesday, 15 May 2013 00:00
- Written by Liz Highleyman
For people with chronic hepatitis C who cannot wait for all-oral regimens, interferon-based therapy is still a reality. Researchers at the recent EASL International Liver Congress (EASL 2013) presented promising data showing that several experimental direct-acting antiviral agents (DAAs) can significantly improve response rates without reducing tolerability.
More Articles...
- EASL 2013: ACH-3102 and Sovaprevir Show Potent Activity, High Barrier to Resistance in Early Studies
- Sofosbuvir/Ledipasvir Coformulation Shows Good Early Response With or Without Ribavirin
- Direct-acting Antivirals Could Dramatically Reduce Hepatitis C Transmission among IDUs
- EASL 2013: Vaniprevir Boosts Interferon/Ribavirin Response Rate for Prior Non-Responders with Cirrhosis
Web Design and Development by